Close Menu

NEW YORK (GenomeWeb) – Using ex vivo 3D (EV-3D) cell culture technology to model and predict a patient's therapeutic response to drugs, startup Kiyatec expects to target the oncology market with ovarian cancer and glioblastoma assays in 2022.

While Kiyatec currently offers a drug discovery service for pharmaceutical partners, the firm is working toward commercializing a clinical service for oncologists, and has begun a validation study for this application.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
21

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.